CLINICAL TRIALS PROFILE FOR ULTRAVIST 240
✉ Email this page to a colleague
All Clinical Trials for ULTRAVIST 240
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00244140 ↗ | Ultravist: Safety and Efficacy in Computed Tomography of Head and Body | Completed | Bayer | Phase 3 | 2005-10-01 | This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body |
| NCT00876083 ↗ | PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination | Completed | Bayer | 2008-03-01 | The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely. | |
| NCT00926562 ↗ | A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients | Completed | Chinese PLA General Hospital | Phase 4 | 2009-02-01 | The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI). |
| NCT01206257 ↗ | The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) | Completed | Bayer | 2010-08-01 | This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity | |
| NCT01255722 ↗ | Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography | Completed | Guerbet | Phase 4 | 2010-11-01 | The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability (quality and interpretability of images). |
| NCT01415414 ↗ | Observational Study of Ultravist in Patients Requiring CECT | Completed | Bayer | 2011-09-01 | It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication. | |
| NCT01448889 ↗ | Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy | Unknown status | Assaf-Harofeh Medical Center | N/A | 2009-09-01 | Acute renal failure induced by radiographic contrast agents is a known complication of coronary angiography.hypoxia plays a major role in the pathogenesis of Contrast induced nephropathy. The aim of the current study is to investigate the effect of normobaric hyperoxygenation therapy on renal functions in patients at high risk for CIN undergoing coronary angiography. The study is aimed to include 180 consecutive patients with estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2 that are candidates for elective coronary angiography. Patients with acute renal failure, acute myocardial infarction, noncompensated congestive heart failure, hemodynamic instability, known sensitivity to contrast media and patients who had been exposed to contrast media during the last 3 months will be excluded. Patients with oxygen blood saturation of less than 94% at room air will also be excluded from the study. Study protocol Patients will be randomly assigned to receive either 100% oxygen by mask (treated group) or breath room air (control group) for duration of 4 hours starting at the beginning of the angiographic procedure. All patients will be treated with 0.9% salin and NAC. Coronary angiography will be performed using nonionic, low osmolar iodine (Ultravist®-370) (Schering, Berlin, Germany). All patients will be hospitalized 1 day before and at least 24 hours following angiography. Blood samples for urea, creatinine and cystatin- C will be drawn on admission, 6, 24 and 48 hours after coronary angiography. Urine sample will be taken 24 hours before angiography and 6, 24 and 48 hours post angiography. In those urine samples the ratio between creatinine to Isoprostanes and NO will be evaluated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ULTRAVIST 240
Condition Name
Clinical Trial Locations for ULTRAVIST 240
Trials by Country
Clinical Trial Progress for ULTRAVIST 240
Clinical Trial Phase
Clinical Trial Sponsors for ULTRAVIST 240
Sponsor Name
